The founding editor-in-chief will redirect his focus to a Parkinson’s organization.

All students’ tuition will be funded through its endowment.

The genetically engineered probiotic, already in clinical trials, may ease patients’ strict dietary regimes.

Epidiolex, a cannabis-derived medicine for epilepsy, will prompt federal regulatory changes that could crack open access to study the plant.

NIDA pharmacologist Michael Baumann explains how “unscrupulous vendors” hijacked compounds used in neuroscience and turned them into dangerous drugs.

It took an international group of researchers 13 years to crack the code and their efforts are already bearing fruit—one study has pinned down the genes responsible for wheat allergies and sensitivity.

The agency proposes ceding its scrutiny of these studies to the FDA.

The plan would move two scientific branches out of Washington, DC, by 2019.

Data don’t support many direct-to-consumer products, from telomere assessments to bespoke diets based on genetic sequences.